Other3

Attovia Therapeutics, Inc.

Total Value

$NaN

Filing Date

Aug 5, 2026

1 transactions

Trade Summary

On Aug 4, 2026, WALSH COLIN, Director, reported $NaN of Attovia Therapeutics, Inc. (ATTO) across 1 transactions. The filing covers company securities and reflects balanced net activity of $NaN. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: WALSH COLIN
Role: Director
Location: NEW YORK, NY

Filing Details

Filing Date: Aug 5, 2026
Transaction Date: Aug 4, 2026
Accession Number: 0001866174-26-000007
Form Type: 3

Want live alerts when WALSH COLIN trades again?

Download Insider Trades to track ATTO, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)The Reporting Person is a managing director of Goldman Sachs & Co LLC ("GS&Co"), a subsidiary of The Goldman Sachs Group Inc. ("GS Group"). GS Group is the direct owner of GS&Co. and an indirect owner of Goldman Sachs Asset Management, L.P. ("GSAM LP"). GS&Co. is the manager of Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock of the Issuer. GSAM LP is the investment manager of WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly owns 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock of the Issuer,... [continued in footnote 2]
(F2)[continued from footnote 1]... West Street Life Sciences I, L.P. ("WSLS I"), which owns 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock of the Issuer, WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which owns 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock of the Issuer, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock of the Issuer.
(F3)The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

WALSH COLIN

(Last)

(First)

(Middle)

C/O GOLDMAN SACHS GROUP INC.

2OO WEST STREET

(Street)

NEW YORK

10282

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/04/2026

3. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series B Preferred Stock	⁽¹⁾⁽²⁾⁽³⁾	⁽¹⁾⁽²⁾⁽³⁾	Common Stock	1,957,140	$0	I	See Footnote⁽¹⁾⁽²⁾⁽³⁾
Series C Preferred Stock	⁽¹⁾⁽²⁾⁽³⁾	⁽¹⁾⁽²⁾⁽³⁾	Common Stock	478,501	$0	I	See Footnote⁽¹⁾⁽²⁾⁽³⁾

Explanation of Responses:

1. The Reporting Person is a managing director of Goldman Sachs & Co LLC ("GS&Co"), a subsidiary of The Goldman Sachs Group Inc. ("GS Group"). GS Group is the direct owner of GS&Co. and an indirect owner of Goldman Sachs Asset Management, L.P. ("GSAM LP"). GS&Co. is the manager of Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock of the Issuer. GSAM LP is the investment manager of WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly owns 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock of the Issuer,... [continued in footnote 2]

2. [continued from footnote 1]... West Street Life Sciences I, L.P. ("WSLS I"), which owns 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock of the Issuer, WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which owns 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock of the Issuer, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock of the Issuer.

3. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Remarks:

	/s/ Crystal Orgill, Attorney-in-fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 3 as rendered by the SEC from accession 0001866174-26-000007.

Attovia Therapeutics, Inc.

Trade Summary

Company Information

Insider Information

Filing Details

Want live alerts when WALSH COLIN trades again?

Footnotes

SEC Form 3

SEC Filing

SEC Form 3